Reuters: Regulatory News: U.S. FDA approves Actelion's lung disease drug Opsumit

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

50% off Print Subscription of USA Today Get the news delivered to your doorstep. Lock in the savings and receive USA Today for just $0.75 a day. From our sponsors

U.S. FDA approves Actelion's lung disease drug Opsumit Oct 18th 2013, 22:31 Share this Email Print Reprints Fri Oct 18, 2013 6:31pm EDT Oct 18 (Reuters) - Actelion Ltd has won U.S. approval for its drug Opsumit, a successor to its pulmonary arterial hypertension drug Tracleer, which loses patent protection in 2015. Pulmonary arterial hypertension, or PAH, is characterized by high blood pressure in the arteries connecting the heart to the lungs, which causes the right side of the heart to work harder than normal and causes shortness of breath. Opsumit belongs to a class of drugs known as endothelin receptor antagonists, which relax the pulmonary arteries and decrease that pressure. The drug, like others in its class, carries a boxed warning, the most serious possible, that it should not be used in pregnant women because it can harm the fetus. The FDA based its approval on a clinical trial that showed Opsumit was effective in slowing progression of the disease. The Swiss company reported sales of Tracleer in 2012 of 1.5 billion francs, making it the company's biggest selling product. Actelion is banking on Opsumit to make up for an expected decline in Tracleer sales once it loses market exclusivity. Opsumit will compete with, among others, Gilead Sciences Inc.'s Letairis, which is sold outside the United States by GlaxoSmithKline Plc under the brand name Volibris. Link this Share this Digg this Email Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions